Our lead development product, EX404, targets PolyCystic Ovarian Syndrome (PCOS) in adolescents and adults. EffRx received an orphan drug designation (ODD) from FDA for the adolescent PCOS in May 2014.
|Product / Project||Indication||Development Phase|
(buffered effervescent alendronate)
|Osteoporosis||Commercialized in multiple markets|
|EX404 (USA)||Adolescent PCOS (orphan)
|IND with FDA
Phase II / III in development